Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

05.01.2023 | short review

Vaccination against SARS-CoV-2 in adults with a diagnosis of cancer: a short review

verfasst von: M.D. Waltraud Elisabeth Huf, M.D. Arschang Valipour

Erschienen in: memo - Magazine of European Medical Oncology

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Compared to individuals without cancer, patients with a diagnosis of malignancy bear a higher risk of becoming infected with SARS-CoV‑2, suffer more frequently from disease-related complications, and are more likely to die due to coronavirus disease 2019 (COVID-19). Depending on the type of cancer and the treatment received, the immune response to vaccination may also be affected in patients with certain types of malignancy. Therefore, there is a need for more specific COVID-19 vaccination recommendations in individuals with a diagnosis of cancer. Furthermore, pre-exposition prophylaxis should be considered for some patients. This short review summarizes some challenges in prevention of (severe) COVID-19 in individuals with a diagnosis of cancer and compares guidelines given by the US National Comprehensive Cancer Network, German Robert Koch-Institut, and Austrian Nationales Impfgremium.
Literatur
1.
Zurück zum Zitat Wang F, Chen L, Wang Z, Xu Q, Huang H, Wang H, et al. Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis. Cancer Cell Int. 2022;22(1):320. CrossRef Wang F, Chen L, Wang Z, Xu Q, Huang H, Wang H, et al. Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis. Cancer Cell Int. 2022;22(1):320. CrossRef
2.
Zurück zum Zitat Alaeddini M, Etemad-Moghadam S. SARS-Cov‑2 infection in cancer patients, susceptibility, outcome and care. Am J Med Sci. 2022;364(5):511–20. CrossRef Alaeddini M, Etemad-Moghadam S. SARS-Cov‑2 infection in cancer patients, susceptibility, outcome and care. Am J Med Sci. 2022;364(5):511–20. CrossRef
3.
Zurück zum Zitat Lee LYW, Starkey T, Ionescu MC, Little M, Tilby M, Tripathy AR, et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncol. 2022;23(6):748–57. CrossRef Lee LYW, Starkey T, Ionescu MC, Little M, Tilby M, Tripathy AR, et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncol. 2022;23(6):748–57. CrossRef
4.
Zurück zum Zitat Di Lorenzo G, Ingenito C, D’Ambrosio B, Ranieri C, Iuliucci MR, Iervolino M, et al. The effect of vaccination against COVID-19 in cancer patients: final results of the COICA trial. Oncology. 2022;100:512–8. CrossRef Di Lorenzo G, Ingenito C, D’Ambrosio B, Ranieri C, Iuliucci MR, Iervolino M, et al. The effect of vaccination against COVID-19 in cancer patients: final results of the COICA trial. Oncology. 2022;100:512–8. CrossRef
5.
Zurück zum Zitat Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV‑2 infection. Nat Med. 2021;27(7):1205–11. CrossRef Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV‑2 infection. Nat Med. 2021;27(7):1205–11. CrossRef
6.
Zurück zum Zitat Tang K, Wei Z, Wu X. Impaired serological response to COVID-19 vaccination following anticancer therapy: a systematic review and meta-analysis. J Med Virol. 2022;94(10):4860–8. CrossRef Tang K, Wei Z, Wu X. Impaired serological response to COVID-19 vaccination following anticancer therapy: a systematic review and meta-analysis. J Med Virol. 2022;94(10):4860–8. CrossRef
7.
Zurück zum Zitat Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, et al. Adaptive immunity and neutralizing antibodies against SARS-coV‑2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2:1321–37. CrossRef Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, et al. Adaptive immunity and neutralizing antibodies against SARS-coV‑2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2:1321–37. CrossRef
8.
Zurück zum Zitat Wagner A, Garner-Spitzer E, Schötta AM, Orola M, Wessely A, Zwazl I, et al. SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in Immunocompromised patients—a phase four study comparing immune responses in patients with solid cancers, multiple myeloma and inflammatory bowel disease. Front Immunol. 2022;13:889138. CrossRef Wagner A, Garner-Spitzer E, Schötta AM, Orola M, Wessely A, Zwazl I, et al. SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in Immunocompromised patients—a phase four study comparing immune responses in patients with solid cancers, multiple myeloma and inflammatory bowel disease. Front Immunol. 2022;13:889138. CrossRef
9.
Zurück zum Zitat Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvadé V, et al. Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. JAMA Oncol. 2022;8(5):e220446. CrossRef Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvadé V, et al. Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. JAMA Oncol. 2022;8(5):e220446. CrossRef
10.
Zurück zum Zitat Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, et al. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV‑2 omicron variant. Cell Rep Med. 2022;3(7):100679. CrossRef Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, et al. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV‑2 omicron variant. Cell Rep Med. 2022;3(7):100679. CrossRef
11.
Zurück zum Zitat Mair MJ, Mitterer M, Gattinger P, Berger JM, Trutschnig W, Bathke AC, et al. Enhanced SARS-CoV‑2 breakthrough infections in patients with hematologic and solid cancers due to omicron. Cancer Cell. 2022;40(5):444–6. CrossRef Mair MJ, Mitterer M, Gattinger P, Berger JM, Trutschnig W, Bathke AC, et al. Enhanced SARS-CoV‑2 breakthrough infections in patients with hematologic and solid cancers due to omicron. Cancer Cell. 2022;40(5):444–6. CrossRef
12.
Zurück zum Zitat Mai AS, Lee A, Tay RYK, Shapiro L, Thakkar A, Halmos B, et al. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. Eur J Cancer. 2022;172:65–75. CrossRef Mai AS, Lee A, Tay RYK, Shapiro L, Thakkar A, Halmos B, et al. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. Eur J Cancer. 2022;172:65–75. CrossRef
13.
Zurück zum Zitat Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, Kragh A, Frederiksen H, et al. Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2022;40(8):800–1. CrossRef Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, Kragh A, Frederiksen H, et al. Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2022;40(8):800–1. CrossRef
14.
Zurück zum Zitat Mair MJ, Berger JM, Mitterer M, Gansterer M, Bathke AC, Trutschnig W, et al. Third dose of SARS-CoV‑2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events—a retrospective cohort study. Eur J Cancer. 2022;165:184–94. CrossRef Mair MJ, Berger JM, Mitterer M, Gansterer M, Bathke AC, Trutschnig W, et al. Third dose of SARS-CoV‑2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events—a retrospective cohort study. Eur J Cancer. 2022;165:184–94. CrossRef
16.
Zurück zum Zitat Fenioux C, Teixeira L, Fourati S, Melica G, Lelievre JD, Gallien S, et al. SARS-CoV‑2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents. JAMA Oncol. 2022;8(4):612–7. CrossRef Fenioux C, Teixeira L, Fourati S, Melica G, Lelievre JD, Gallien S, et al. SARS-CoV‑2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents. JAMA Oncol. 2022;8(4):612–7. CrossRef
17.
Zurück zum Zitat Keam B, Kim MK, Choi Y, Choi SJ, Choe PG, Lee KH, et al. Optimal timing of influenza vaccination during 3‑week cytotoxic chemotherapy cycles. Cancer. 2017;123(5):841–8. CrossRef Keam B, Kim MK, Choi Y, Choi SJ, Choe PG, Lee KH, et al. Optimal timing of influenza vaccination during 3‑week cytotoxic chemotherapy cycles. Cancer. 2017;123(5):841–8. CrossRef
18.
Zurück zum Zitat Wumkes ML, van der Velden AM, Los M, Leys MB, Beeker A, Nijziel MR, et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine. 2013;31(52):6177–84. CrossRef Wumkes ML, van der Velden AM, Los M, Leys MB, Beeker A, Nijziel MR, et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine. 2013;31(52):6177–84. CrossRef
19.
Zurück zum Zitat Zerbit J, Detroit M, Meyer A, Decroocq J, Deau-Fischer B, Deschamps P, et al. Patients with hematological malignancies treated with T‑cell or B‑cell immunotherapy remain at high risk of severe forms of COVID-19 in the omicron era. Viruses. 2022;14(11):2377. CrossRef Zerbit J, Detroit M, Meyer A, Decroocq J, Deau-Fischer B, Deschamps P, et al. Patients with hematological malignancies treated with T‑cell or B‑cell immunotherapy remain at high risk of severe forms of COVID-19 in the omicron era. Viruses. 2022;14(11):2377. CrossRef
20.
Zurück zum Zitat Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wörmann B, Turajlic S, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022;19(6):385–401. CrossRef Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wörmann B, Turajlic S, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022;19(6):385–401. CrossRef
21.
Zurück zum Zitat Chen S, Guan F, Candotti F, Benlagha K, Camara NOS, Herrada AA, et al. The role of B cells in COVID-19 infection and vaccination. Front Immunol. 2022;13:988536. CrossRef Chen S, Guan F, Candotti F, Benlagha K, Camara NOS, Herrada AA, et al. The role of B cells in COVID-19 infection and vaccination. Front Immunol. 2022;13:988536. CrossRef
22.
Zurück zum Zitat NCCN. NCCN: cancer and COVID-10 vaccination. 2022. Version 7.0 09/22/20222022. NCCN. NCCN: cancer and COVID-10 vaccination. 2022. Version 7.0 09/22/20222022.
23.
Zurück zum Zitat Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW. Susceptibility of SARS-CoV‑2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Microbiol Spectr. 2022;10(4):e92622. CrossRef Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW. Susceptibility of SARS-CoV‑2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Microbiol Spectr. 2022;10(4):e92622. CrossRef
24.
Zurück zum Zitat Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387:468–70. CrossRef Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387:468–70. CrossRef
26.
Zurück zum Zitat RKI. Epidemiol Bull. 2022;40:14–18. RKI. Epidemiol Bull. 2022;40:14–18.
28.
Zurück zum Zitat Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, et al. Activity of AZD7442 (tixagevimab-cilgavimab) against omicron SARS-CoV‑2 in patients with hematologic malignancies. Cancer Cell. 2022;40(6):590–1. CrossRef Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, et al. Activity of AZD7442 (tixagevimab-cilgavimab) against omicron SARS-CoV‑2 in patients with hematologic malignancies. Cancer Cell. 2022;40(6):590–1. CrossRef
Metadaten
Titel
Vaccination against SARS-CoV-2 in adults with a diagnosis of cancer: a short review
verfasst von
M.D. Waltraud Elisabeth Huf
M.D. Arschang Valipour
Publikationsdatum
05.01.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00858-x